S&P 500
5,911.69
-0.0%
-$0.48
DJI
42,270.07
+0.1%
+$54.34
NASDAQ
19,113.77
-0.3%
-$62.11
Bitcoin
104,112.00
-0.0%
-19.93
AAPL
$201.47
+0.8%
+$1.52
AMZN
$205.07
-0.3%
-$0.63
GOOG
$173.06
+0.1%
+$0.10
META
$648.23
+0.5%
+$3.18
MSFT
$460.71
+0.4%
+$2.03
NVDA
$135.22
-2.9%
-$3.97
TSLA
$346.82
-3.2%
-$11.61
The Conversation
TheConversation
The Conversation is a not-for-profit publication that seeks to unlock knowledge from experts for the public. It works with hundreds of academics around the world, all experts in their fields, to deliver in-depth analysis to millions of readers around the world. These experts explain what they've learned from years and sometimes decades of research on issues in the news, and on topics ranging from art to zoology.
Recent Articles by The Conversation

Jun 25, 2019
by The Conversation
Cheaper Versions of the Most Expensive Drugs May be Coming, but Monopolies Will Likely Remain
Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.